राष्ट्र प्रहरी
@bevocal_india
My work defines me..
ID: 1925609378
02-10-2013 04:18:59
8,8K Tweet
277 Takipçi
69 Takip Edilen
#Day1508GIPSAWageRevision please look into the issue without further delay as 4 year plus delay us nothing but denying employees rights that too during these inflationary and covid times even though we served the community whole heartedly Nirmala Sitharaman Nirmala Sitharaman Office DFS
Nirmala Sitharaman Nirmala Sitharaman Office DFS #Day1508GIPSAWageRevision Only gipsa employees nd their families are to suffer,rest all have been taken care off. We executed low priced corona policies as directed and as required by the masses which resulted in claims,wt is our fault?
Expressions given by DFS Ministry of Finance Nirmala Sitharaman when psgic sector employees ask for #GIPSAWAGEREVISION which is pending since last 54 months. Even though work load is increasing,TP claims pay out and millions of covid claims are being settled by psu insurers.
Nirmala Sitharaman Office Nirmala Sitharaman Narendra Modi PIB India PIB in Andhra Pradesh Ministry of Finance Ministry of Information and Broadcasting DD News All India Radio News Nirmala Sitharaman Office Respected Madam अब GIPSA कर्मचारियों की “मन की बात” भी सुनिए। 41 months of waiting is not governance. From Crisis Duty to Strike Duty — You Left Us No Choice Strike on 9 Jan 2026 #GIPSAWageRevision #PSGIC_WR_Strike #FailedAssurance DFS Ministry of Finance
Nirmala Sitharaman Office Nirmala Sitharaman Narendra Modi Nirmala Sitharaman Office Respected Madam अब GIPSA कर्मचारियों की “मन की बात” भी सुनिए। 41 months of waiting is not governance. From Crisis Duty to Strike Duty — You Left Us No Choice Strike on 9 Jan 2026 #GIPSAWageRevision #PSGIC_WR_Strike #FailedAssurance DFS Ministry of Finance
कर्तव्य निभाया हर हाल में, वेतन अटका सवाल में! #GIPSAWageRevision #PSGIC_WR_Strike #FailedAssurance DFS Ministry of Finance PMO India NDTV India AajTak WE_INSURERS Naga Sai PSGIC karmachari
कुछ प्राइवेट फार्मा कंपनियाँ ब्रांडेड दवाइयों (medicines) पर 600% से 1000% तक मुनाफ़ा कमा रही हैं। यह कोई आरोप नहीं, बल्कि संसद की समिति की रिपोर्ट में दर्ज तथ्य है। जहाँ वही दवा generic रूप में 80-90% सस्ती मिल सकती है, वहीं सिर्फ ब्रांड के नाम पर आम आदमी से कई गुना कीमत वसूली